Next Article in Journal
A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor
Next Article in Special Issue
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
Previous Article in Journal
The Role of Equine Herpesvirus Type 4 Glycoprotein K in Virus Replication
Previous Article in Special Issue
RNA-Sequencing Analysis of 5' Capped RNAs Identifies Many New Differentially Expressed Genes in Acute Hepatitis C Virus Infection
Viruses 2012, 4(8), 1264-1278; doi:10.3390/v4081264

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin

1,* , 1,2
Received: 12 June 2012 / Revised: 27 July 2012 / Accepted: 6 August 2012 / Published: 14 August 2012
(This article belongs to the Special Issue Hepatitis C Pathology)
View Full-Text   |   Download PDF [686 KB, uploaded 12 May 2015]   |   Browse Figure


It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. In the present study, we examined how ITPA and IL28B genotypes have clinical impacts on treatment-induced hematotoxicities and treatment response in HCV-infected patients treated with peginterferon plus ribavirin. ITPA genotypes (rs1127354 and rs6051702) and IL28B genotype (rs8099917) were determined by TaqMan SNP assay. We compared clinical background, treatment course and treatment response in terms of these genotypes. Only IL28B rs8099917 major type could predict sustained virological response. ITPA rs1127354 major type leads to significantly greater ribavirin-induced anemia than ITPA rs1127354 minor type between days 0 and 84. We noticed that IL28B rs8099917 minor genotype was associated with higher reduction of neutrophils and platelets. ITPA rs1127354 is useful for the prediction of ribavirin-induced anemia in the early phase after the commencement of peginterferon plus ribavirin treatment and IL28B rs8099917 is useful for the prediction of sustained virological response. Use of the combination of these two genotypes could lead to safe and effective treatment of chronic hepatitis C patients.
Keywords: anemia; HCV; IL28B; ITPA; SNP; sustained virological response anemia; HCV; IL28B; ITPA; SNP; sustained virological response
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Miyamura, T.; Kanda, T.; Nakamoto, S.; Wu, S.; Jiang, X.; Arai, M.; Fujiwara, K.; Imazeki, F.; Yokosuka, O. Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin. Viruses 2012, 4, 1264-1278.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert